Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Account Payables: 2009-2024

Historic Change in Account Payables for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to $8.5 million.

  • Heron Therapeutics' Change in Account Payables rose 47.37% to -$20,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 78.04%. This contributed to the annual value of $8.5 million for FY2024, which is 56360.00% up from last year.
  • As of FY2024, Heron Therapeutics' Change in Account Payables stood at $8.5 million, which was up 56,360.00% from $15,000 recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Change in Account Payables registered a high of $8.5 million during FY2024, and its lowest value of -$2.2 million during FY2020.
  • Moreover, its 3-year median value for Change in Account Payables was $15,000 (2023), whereas its average is $2.6 million.
  • Its Change in Account Payables has fluctuated over the past 5 years, first tumbled by 117.63% in 2022, then skyrocketed by 56,360.00% in 2024.
  • Yearly analysis of 5 years shows Heron Therapeutics' Change in Account Payables stood at -$2.2 million in 2020, then soared by 246.80% to $3.3 million in 2021, then plummeted by 117.63% to -$578,000 in 2022, then surged by 102.60% to $15,000 in 2023, then skyrocketed by 56,360.00% to $8.5 million in 2024.